|Bid||57.00 x 800|
|Ask||57.05 x 1800|
|Day's range||50.88 - 57.55|
|52-week range||34.88 - 277.80|
|Beta (5Y monthly)||1.33|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2022 - 04 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||183.40|
Indeed, the S&P 500 is in bear market territory, defined as a 20% (or more) drop from its most recent high. Take biotech company Novavax (NASDAQ: NVAX). While the broader market sell-off hasn't helped Novavax, the company has encountered its own issues, too.
In the latest trading session, Novavax (NVAX) closed at $51.43, marking a -0.81% move from the previous day.
The FDA is asking COVID-19 vaccine makers to test and produce boosters that target both the original and new BA.4/BA.5 strains of the virus by fall.